Susceptibility to viral and mycobacterial infections due to STAT1 deficiency

Susceptibility to viral and mycobacterial infections due to STAT1 deficiency (also known as STAT1 deficiency, complete or partial) is a rare primary immunodeficiency caused by mutations in the STAT1 gene, which encodes a critical transcription factor in the interferon (IFN) signaling pathways. STAT1 plays an essential role in mediating cellular responses to both type I interferons (IFN-α/β) and type II interferon (IFN-γ), which are crucial for defense against viral and mycobacterial pathogens, respectively. Complete autosomal recessive STAT1 deficiency impairs both IFN-α/β and IFN-γ signaling, leading to severe susceptibility to both intracellular bacteria (particularly mycobacteria, including BCG and environmental mycobacteria) and viral infections (such as herpes simplex virus and other herpesviruses). Partial STAT1 deficiency may present with a somewhat milder phenotype but still carries significant infectious risk. The disease primarily affects the immune system, but because infections can involve multiple organ systems, patients may present with disseminated mycobacterial disease affecting the lungs, lymph nodes, bones, and other organs, as well as severe or recurrent viral infections including life-threatening herpesviral encephalitis or disseminated viral disease. Onset is typically in infancy or early childhood, often following BCG vaccination in countries where this is routinely administered. Patients with complete STAT1 deficiency generally have a more severe clinical course and poorer prognosis compared to those with partial deficiency. Treatment involves aggressive antimicrobial therapy for active infections, including prolonged courses of antimycobacterial drugs and antiviral agents. Prophylactic antibiotics and antiviral medications may be used to prevent recurrent infections. Interferon-gamma therapy has limited utility in complete deficiency since the signaling pathway is impaired. Hematopoietic stem cell transplantation (HSCT) represents the only potentially curative treatment, particularly for patients with complete STAT1 deficiency, and is considered in severe cases where conventional management is insufficient to control life-threatening infections.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Susceptibility to viral and mycobacterial infections due to STAT1 deficiency